Cite
HARVARD Citation
Neumair, P. et al. (2016). Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung cancer. pp. 38-44. [Online].